These experimental payloads are designed to damage selected DNA sequences. They are related to other DNA-binding payloads but have their own chemistry and evidence.
Pyridinobenzodiazepines, or PDDs, are sequence-selective DNA mono-alkylators. A primary study linked a PDD monomer derivative to trastuzumab and reported activity in a pancreatic cancer xenograft model. The results support a preclinical payload concept. They do not establish a clinical advantage over TOP1 conjugates or justify assigning the crosslinking mechanism of PBD dimers to PDD monomers.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares DNA alkylator payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/